<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>CONTEXT: <z:e sem="disease" ids="C0024408" disease_type="Disease or Syndrome" abbrv="MJD|SCA3">Machado-Joseph Disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e>) is an <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> <z:hpo ids='HP_0002503'>spinocerebellar degeneration</z:hpo> that evolves to disability and <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Experimental data have shown that <z:chebi fb="19" ids="28790">serotonin</z:chebi> is an important cerebellar neurotransmitter and that impairment of the serotoninergic cerebellar system can induce <z:hpo ids='HP_0001251'>cerebellar ataxia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>OBJECTIVES: To evaluate the efficacy of <z:chebi fb="0" ids="5118">fluoxetine</z:chebi>, a <z:chebi fb="19" ids="28790">serotonin</z:chebi> reuptake inhibitor, in treating neurologic dysfunction in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS AND METHODS: Thirteen <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> patients were treated with <z:chebi fb="0" ids="5118">fluoxetine</z:chebi> (20 mg/day) and were followed-up for 6 weeks </plain></SENT>
<SENT sid="4" pm="."><plain>Outcome measures included functional capacity, standardized neurologic and cognitive ratings </plain></SENT>
<SENT sid="5" pm="."><plain>The Montgomery-Asberg <z:hpo ids='HP_0000716'>depression</z:hpo> rating scale was used to control depressive symptoms </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: There was no significant improvement in motor abilities after 6 weeks of treatment </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: These results suggest that <z:chebi fb="0" ids="5118">fluoxetine</z:chebi> has no benefit in motor function of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e> </plain></SENT>
</text></document>